Antibody Information
General Information of This Antibody
| Antibody ID | ANTI0HTBYC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | h3E1 |
|||||
| Organization | Hyogo Medical University School of Medicine; First People's Hospital of Foshan; Kindai University. |
|||||
| Synonyms |
h3E1
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized lgG4 |
|||||
| Antigen Name | Cell adhesion molecule 1 (CADM1) |
Antigen Info | ||||
| Click to Show/Hide the Sequence Information of This Antibody | ||||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
h3E1-MMAE ADC [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.04 nM
|
Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Type II endometrial adenocarcinoma | HEC-50B cells | CVCL_2929 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
12.02 nM
|
Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | HEC-1B cells | CVCL_0294 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
13.03 nM
|
Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Uveal melanoma | OCM-2 cells | CVCL_6936 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
24.32 nM
|
Positive CADM1 expression (CADM1+++/++) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | JHUM-3 cells | CVCL_4657 | ||
| Experiment 5 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) | > 1000 nM | Negative CADM1 expression (CADM1 -) | ||
| Method Description |
Killing of endometrial adenocarcinoma cells by h3E1-MMAE ADC. Endometrial adenocarcinoma cells were cultured in a 96-well plate at 30% confluence, and either hIgG-MMAE or h3E1-MMAE ADC was added at indicated concentrations. After 5 days, cell viability was calculated by WST-8 assays in triplicate. The mean is plotted in a line graph, with a thin vertical line indicating the standard deviation. a and b, P-value <.05 and .01, respectively, when compared with the value of h3E1-MMAE ADC at the identical concentration. IC50 (ug/ml and nM) is calculated.
Click to Show/Hide
|
||||
| In Vitro Model | Endometrial adenocarcinoma | HHUA cells | CVCL_3866 | ||
References